How often are cosentyx dosage increases typically made?

How often are Cosentyx dosage increases typically made?

Cosentyx (secukinumab) is usually kept at the same dose after loading. The standard adult dose for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis is 300 mg or 150 mg once monthly after four or five weekly 300 mg or 150 mg loading doses. Providers rarely increase the dose once maintenance begins.

Can providers raise the dose if symptoms return?

Some clinicians increase to 300 mg if patients are on 150 mg and show insufficient response. These adjustments happen after the ersten 16–24 weeks of treatment, once maintenance efficacy is evaluated. Increases happen infrequently and are decided case by case.

How does this compared to other biologics?

Other biologics like adalimumab or ustekinumab allow dose escalation earlier and more frequently. Cosentyx guidelines recommend staying at the approved dose rather than titrating upward. Label information shows limited allowance for 300 mg versus 150 mg choice rather than real-time adjustments.

When does the Cosentyx patent expire?

The main U.S. patent covering secukinumab expires in 2025. [1]

What alternatives exist if higher doses are needed?

Switching to another biologic is more common than raising Cosentyx itself. Options include TNF inhibitors, IL-17A inhibitors with similar action, or new entrants in the IL-17A/F dual inhibitors.